VX-765: Selective Caspase-1 Inhibitor for Inflammation and Pyroptosis Research

Executive Summary: VX-765 is a highly selective, orally absorbed pro-drug inhibitor of caspase-1, also known as interleukin-1 converting enzyme (ICE), and is metabolized in vivo to its active form VRT-043198 (APExBIO). It specifically reduces the release of pro-inflammatory cytokines IL-1β and IL-18 without affecting other cytokines such as IL-6, IL-8, or TNFα (Panina et al. 2019). VX-765 is a valuable tool for dissecting caspase-1–mediated inflammatory pathways and pyroptosis in macrophages. Its efficacy has been demonstrated in preclinical models of arthritis, skin inflammation, and HIV-associated CD4 T-cell pyroptosis. VX-765 is supplied by APExBIO (Cat. No. A8238) in a stable, solid form for research use only.

Biological Rationale

Caspase-1 is a cysteine protease, part of the ICE-like subfamily, that cleaves pro-IL-1β and pro-IL-18 to generate their active, secreted forms (Panina et al. 2019). This process is central to the innate inflammatory response and mediates the release of cytokines essential for host defense and disease pathogenesis. Aberrant caspase-1 activity has been implicated in autoimmune diseases, autoinflammatory syndromes, and cell death by pyroptosis—a lytic, inflammatory form of programmed cell death particularly relevant in macrophages during bacterial infection. Selective inhibition of caspase-1 enables precise dissection of the inflammasome pathway and its contribution to disease models, distinguishing it from broader caspase family inhibitors that lack specificity and can confound interpretation by affecting apoptosis or non-canonical cell death pathways (see related review—this article provides an updated focus on selectivity).

Mechanism of Action of VX-765

VX-765 is an orally bioavailable pro-drug that is metabolized in vivo to its active form, VRT-043198 (APExBIO). VRT-043198 binds reversibly to the active site of caspase-1, inhibiting the enzyme's ability to cleave pro-IL-1β and pro-IL-18. This results in decreased maturation and secretion of these cytokines. Notably, VX-765 does not inhibit other caspases (such as caspase-3 or -8), nor does it reduce levels of unrelated cytokines like IL-6, IL-8, TNFα, or IL-α—demonstrating high selectivity for the caspase-1/ICE pathway (for a mechanistic deep-dive, see this resource; this article emphasizes practical research integration). In cellular assays, VX-765 blocks caspase-1–dependent pyroptosis in macrophages and prevents caspase-1–mediated CD4 T-cell death in HIV-infected tissue models.

Evidence & Benchmarks

• VX-765 reduces IL-1β and IL-18 secretion in human immune cell assays without affecting TNFα or IL-6 levels (Panina et al. 2019).
• In collagen-induced arthritis mouse models, VX-765 significantly decreases joint inflammation and cytokine release at oral dosages of 25–100 mg/kg/day (APExBIO).
• VX-765 prevents CD4 T-cell pyroptotic death in HIV-infected ex vivo lymphoid tissues in a dose-dependent manner (see Figure 2 in Panina et al. 2019).
• Active metabolite VRT-043198 achieves >90% inhibition of caspase-1 activity at 1–10 μM in biochemical assays (buffered at pH 7.5, 37°C, with 10% DMSO).
• No significant inhibition of caspase-3, -6, -8, or -9 observed at ≤100 μM, confirming pathway specificity (see prior study; this article updates clinical translation aspects).
• In skin inflammation models, VX-765 reduces edema and inflammatory cell infiltration compared to vehicle controls.

Applications, Limits & Misconceptions

VX-765 is a reference inhibitor for dissecting the role of caspase-1 in inflammatory cytokine release and pyroptosis. It is widely used in research models of rheumatoid arthritis, skin inflammation, sepsis, and HIV-associated immune cell depletion. Selectivity for caspase-1 makes it suitable for distinguishing canonical inflammasome pathways from other forms of cell death or inflammation (for more on mitochondrial crosstalk, see this comparative analysis; this article delineates benchmark protocols).

Common Pitfalls or Misconceptions

• VX-765 does not inhibit apoptotic caspases: It is not suitable for apoptosis research targeting caspase-3, -6, -7, -8, or -9.
• Not active in the absence of caspase-1: Ineffective in models lacking canonical inflammasome activation.
• Does not block non-cytokine inflammatory mediators: VX-765 selectively reduces IL-1β and IL-18 but not prostaglandins or chemokines.
• Solubility limits in aqueous buffers: VX-765 is insoluble in water; use DMSO or ethanol with ultrasonic assistance for stock solutions.
• Therapeutic claims unproven: VX-765 is not approved for clinical use; current data are preclinical or early-stage.

Workflow Integration & Parameters

VX-765 (APExBIO A8238) is supplied as a solid, stable at -20°C when desiccated. For in vitro use, prepare stock solutions in DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL with sonication). Working concentrations typically range from 0.1–50 μM in cell culture, with final DMSO kept ≤0.1%. Enzyme inhibition assays are performed at pH 7.5, 25–37°C, with stabilizing additives as required. Solutions should be freshly prepared for short-term use only. For in vivo models, oral dosing between 25–100 mg/kg/day has shown efficacy in mice. Reference protocols and handling instructions are available at the APExBIO VX-765 product page.

Conclusion & Outlook

VX-765 is a benchmark caspase-1 inhibitor, enabling targeted investigation of inflammasome-driven pathways in inflammation and pyroptosis. Its selectivity and favorable pharmacokinetics support its use in diverse disease models. Ongoing research explores therapeutic potential in epilepsy and autoimmune conditions. For full usage parameters and supporting data, visit the APExBIO VX-765 product page. This article extends prior reviews by integrating updated benchmark data and workflow recommendations for translational research.